FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 333:1662-1669 December 21, 1995 Number 25 Next

	Full Text PDF Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background The reverse-transcriptase inhibitor lamivudine has in vitro synergy with zidovudine against the human immunodeficiency virus (HIV). We studied the activity and safety of lamivudine plus zidovudine as compared with either drug alone as treatment for patients with HIV infection, most of whom had not previously received zidovudine.

Methods Three hundred sixty-six patients with 200 to 500 CD4+ cells per cubic millimeter who had received zidovudine for four weeks or less were randomly assigned to treatment with one of four regimens: 300 mg of lamivudine every 12 hours; 200 mg of zidovudine every 8 hours; 150 mg of lamivudine every 12 hours plus zidovudine; or 300 mg of lamivudine every 12 hours plus zidovudine. The study was double-blind and lasted 24 weeks, with an extension phase for another 28 weeks.

Results Over the 24-week period, the low-dose and high-dose regimens combining lamivudine and zidovudine were associated with greater increases in the CD4+ cell count (P = 0.002 and P = 0.015, respectively) and the percentage of CD4+ cells (P<0.001 for both) and with greater decreases in plasma levels of HIV type 1 (HIV-1) RNA (P<0.001 for both) than was treatment with zidovudine alone. Combination therapy was also more effective than lamivudine alone in lowering plasma HIV-1 RNA levels and increasing the percentage of CD4+ cells (P<0.001 for all comparisons), and these advantages persisted through 52 weeks. Adverse events were no more frequent with combination therapy than with zidovudine alone.

Conclusions In HIV-infected patients with little or no prior antiretroviral therapy, treatment with a combination of lamivudine and zidovudine is well tolerated over a one-year period and produces more improvement in immunologic and virologic measures than does treatment with either agent alone.

Source Information

From the University of North Carolina at Chapel Hill, Chapel Hill (J.J.E.); Glaxo Wellcome, Research Triangle Park, N.C. (S.L.B., J.B.Q., M.A.F., M.R.); the Nalle Clinic, Charlotte, N.C. (J.J.); the Medical College of Ohio, Toledo (R.D.M.); the San Juan AIDS Institute, Santurce, Puerto Rico (J.S.); and the University of Colorado Health Sciences Center and Veterans Affairs Medical Center, Denver (D.R.K.). Presented in part at the Second National Conference on Human Retroviruses and Related Infections, Washington, D.C., January 29–February 2, 1995.

Address reprint requests to Dr. Eron at the School of Medicine, CB# 7030, 547 Burnett-Womack, the University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7030.

Full Text of this Article

This article has been cited by other articles:

• Aoki, M., Venzon, D. J., Koh, Y., Aoki-Ogata, H., Miyakawa, T., Yoshimura, K., Maeda, K., Mitsuya, H. (2009). Non-Cleavage Site Gag Mutations in Amprenavir-Resistant Human Immunodeficiency Virus Type 1 (HIV-1) Predispose HIV-1 to Rapid Acquisition of Amprenavir Resistance but Delay Development of Resistance to Other Protease Inhibitors. J. Virol. 83: 3059-3068 [Abstract] [Full Text]  
• Zelina, S., Sheen, C.-W., Radzio, J., Mellors, J. W., Sluis-Cremer, N. (2008). Mechanisms by Which the G333D Mutation in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Facilitates Dual Resistance to Zidovudine and Lamivudine. Antimicrob. Agents Chemother. 52: 157-163 [Abstract] [Full Text]  
• Flynn, P. M., Rodman, J., Lindsey, J. C., Robbins, B., Capparelli, E., Knapp, K. M., Rodriguez, J. F., McNamara, J., Serchuck, L., Heckman, B., Martinez, J., the PACTG P1012 Team, (2007). Intracellular Pharmacokinetics of Once versus Twice Daily Zidovudine and Lamivudine in Adolescents. Antimicrob. Agents Chemother. 51: 3516-3522 [Abstract] [Full Text]  
• Chan-Tack, K. M., Edozien, A. (2006). Lamivudine Monotherapy in an HIV-Infected Patient With the M184V Mutation. J Int Assoc Physicians AIDS Care (Chic Ill) 5: 121-122  
• Hammer, S. M., Saag, M. S., Schechter, M., Montaner, J. S. G., Schooley, R. T., Jacobsen, D. M., Thompson, M. A., Carpenter, C. C. J., Fischl, M. A., Gazzard, B. G., Gatell, J. M., Hirsch, M. S., Katzenstein, D. A., Richman, D. D., Vella, S., Yeni, P. G., Volberding, P. A. (2006). Treatment for Adult HIV Infection: 2006 Recommendations of the International AIDS Society-USA Panel. JAMA 296: 827-843 [Abstract] [Full Text]  
• Monie, D., Simmons, R. P., Nettles, R. E., Kieffer, T. L., Zhou, Y., Zhang, H., Karmon, S., Ingersoll, R., Chadwick, K., Zhang, H., Margolick, J. B., Quinn, T. C., Ray, S. C., Wind-Rotolo, M., Miller, M., Persaud, D., Siliciano, R. F. (2005). A Novel Assay Allows Genotyping of the Latent Reservoir for Human Immunodeficiency Virus Type 1 in the Resting CD4+ T Cells of Viremic Patients. J. Virol. 79: 5185-5202 [Abstract] [Full Text]  
• Asif, G., Hurwitz, S. J., Gumina, G., Chu, C. K., McClure, H. M., Schinazi, R. F. (2005). Pharmacokinetics of the Antiviral Agent {beta}-L-3'-Fluoro-2',3'-Didehydro-2',3'-Dideoxycytidine in Rhesus Monkeys. Antimicrob. Agents Chemother. 49: 560-564 [Abstract] [Full Text]  
• Zapor, M. J., Cozza, K. L., Wynn, G. H., Wortmann, G. W., Armstrong, S. C. (2004). Antiretrovirals, Part II: Focus on Non-Protease Inhibitor Antiretrovirals (NRTIs, NNRTIs, and Fusion Inhibitors). Psychosomatics 45: 524-535 [Abstract] [Full Text]  
• Delaney, W. E. IV, Yang, H., Miller, M. D., Gibbs, C. S., Xiong, S. (2004). Combinations of Adefovir with Nucleoside Analogs Produce Additive Antiviral Effects against Hepatitis B Virus In Vitro. Antimicrob. Agents Chemother. 48: 3702-3710 [Abstract] [Full Text]  
• Rotheram-Borus, M. J., Lee, M., Lin, Y.-Y., Lester, P. (2004). Six-Year Intervention Outcomes for Adolescent Children of Parents With the Human Immunodeficiency Virus. Arch Pediatr Adolesc Med 158: 742-748 [Abstract] [Full Text]  
• Kim, H., Yin, J. (2004). Quantitative Analysis of a Parasitic Antiviral Strategy. Antimicrob. Agents Chemother. 48: 1017-1020 [Abstract] [Full Text]  
• Yuen, G. J., Lou, Y., Bumgarner, N. F., Bishop, J. P., Smith, G. A., Otto, V. R., Hoelscher, D. D. (2004). Equivalent Steady-State Pharmacokinetics of Lamivudine in Plasma and Lamivudine Triphosphate within Cells following Administration of Lamivudine at 300 Milligrams Once Daily and 150 Milligrams Twice Daily. Antimicrob. Agents Chemother. 48: 176-182 [Abstract] [Full Text]  
• Turner, D., Brenner, B., Wainberg, M. A. (2004). Relationships among various nucleoside resistance-conferring mutations in the reverse transcriptase of HIV-1. J Antimicrob Chemother 53: 53-57 [Abstract] [Full Text]  
• Turner, D., Brenner, B., Wainberg, M. A. (2003). Multiple Effects of the M184V Resistance Mutation in the Reverse Transcriptase of Human Immunodeficiency Virus Type 1. CVI 10: 979-981 [Full Text]  
• Diallo, K., Brenner, B., Oliveira, M., Moisi, D., Detorio, M., Gotte, M., Wainberg, M. A. (2003). The M184V Substitution in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Delays the Development of Resistance to Amprenavir and Efavirenz in Subtype B and C Clinical Isolates. Antimicrob. Agents Chemother. 47: 2376-2379 [Abstract] [Full Text]  
• Nicastri, E., Sarmati, L., d'Ettorre, G., Parisi, S. G., Palmisano, L., Galluzzo, C., Montano, M., Uccella, I., Amici, R., Gatti, F., Vullo, V., Concia, E., Vella, S., Andreoni, M. (2003). High Prevalence of M184 Mutation among Patients with Viroimmunologic Discordant Responses to Highly Active Antiretroviral Therapy and Outcomes after Change of Therapy Guided by Genotypic Analysis. J. Clin. Microbiol. 41: 3007-3012 [Abstract] [Full Text]  
• Chen, H., Pai, S. B., Hurwitz, S. J., Chu, C. K., Glazkova, Y., McClure, H. M., Feitelson, M., Schinazi, R. F. (2003). Antiviral Activity and Pharmacokinetics of 1-(2,3-Dideoxy-2-Fluoro-{beta}-L-Glyceropent-2-Enofuranosyl)Cytosine. Antimicrob. Agents Chemother. 47: 1922-1928 [Abstract] [Full Text]  
• Murry, J. P., Higgins, J., Matthews, T. B., Huang, V. Y., Van Rompay, K. K. A., Pedersen, N. C., North, T. W. (2002). Reversion of the M184V Mutation in Simian Immunodeficiency Virus Reverse Transcriptase Is Selected by Tenofovir, Even in the Presence of Lamivudine. J. Virol. 77: 1120-1130 [Abstract] [Full Text]  
• Barbour, J. D., Wrin, T., Grant, R. M., Martin, J. N., Segal, M. R., Petropoulos, C. J., Deeks, S. G. (2002). Evolution of Phenotypic Drug Susceptibility and Viral Replication Capacity during Long-Term Virologic Failure of Protease Inhibitor Therapy in Human Immunodeficiency Virus-Infected Adults. J. Virol. 76: 11104-11112 [Abstract] [Full Text]  
• Bohjanen, P. R., Johnson, M. D., Szczech, L. A., Wray, D. W., Petros, W. P., Miller, C. R., Hicks, C. B. (2002). Steady-State Pharmacokinetics of Lamivudine in Human Immunodeficiency Virus-Infected Patients with End-Stage Renal Disease Receiving Chronic Dialysis. Antimicrob. Agents Chemother. 46: 2387-2392 [Abstract] [Full Text]  
• Van Rompay, K. K. A., Matthews, T. B., Higgins, J., Canfield, D. R., Tarara, R. P., Wainberg, M. A., Schinazi, R. F., Pedersen, N. C., North, T. W. (2002). Virulence and Reduced Fitness of Simian Immunodeficiency Virus with the M184V Mutation in Reverse Transcriptase. J. Virol. 76: 6083-6092 [Abstract] [Full Text]  
• Shafer, R. W. (2002). Genotypic Testing for Human Immunodeficiency Virus Type 1 Drug Resistance. Clin. Microbiol. Rev. 15: 247-277 [Abstract] [Full Text]  
• Jordan, R., Gold, L., Cummins, C., Hyde, C. (2002). Systematic review and meta-analysis of evidence for increasing numbers of drugs in antiretroviral combination therapy. BMJ 324: 757-757 [Abstract] [Full Text]  
• Smith, N P, Pozniak, A L (2002). The changing face of HIV. Imaging 14: 1-7 [Abstract] [Full Text]  
• Sáez-Llorens, X., Nelson Jr, R. P., Emmanuel, P., Wiznia, A., Mitchell, C., Church, J. A., Sleasman, J., Van Dyke, R., Richardson, C. G., Cutrell, A., Spreen, W., Hetherington, S., the CNAA3006 Study Team, (2001). A Randomized, Double-Blind Study of Triple Nucleoside Therapy of Abacavir, Lamivudine, and Zidovudine Versus Lamivudine and Zidovudine in Previously Treated Human Immunodeficiency Virus Type 1-Infected Children. Pediatrics 107: 4e-4 [Abstract] [Full Text]  
• Conry, J. M. (2000). Significant Drug Interactions in the HIV Patient. Journal of Pharmacy Practice 13: 499-514 [Abstract]  
• Sierra, S., Dávila, M., Lowenstein, P. R., Domingo, E. (2000). Response of Foot-and-Mouth Disease Virus to Increased Mutagenesis: Influence of Viral Load and Fitness in Loss of Infectivity. J. Virol. 74: 8316-8323 [Abstract] [Full Text]  
• Beltrami, E. M., Williams, I. T., Shapiro, C. N., Chamberland, M. E. (2000). Risk and Management of Blood-Borne Infections in Health Care Workers. Clin. Microbiol. Rev. 13: 385-407 [Abstract] [Full Text]  
• Descamps, D., Flandre, P., Calvez, V., Peytavin, G., Meiffredy, V., Collin, G., Delaugerre, C., Robert-Delmas, S., Bazin, B., Aboulker, J. P., Pialoux, G., Raffi, F., Brun-Vezinet, F., for the Trilege Study Team, (2000). Mechanisms of Virologic Failure in Previously Untreated HIV-Infected Patients From a Trial of Induction-Maintenance Therapy. JAMA 283: 205-211 [Abstract] [Full Text]  
• Moore, K. H. P., Yuen, G. J., Hussey, E. K., Pakes, G. E., Eron, J. J. Jr., Bartlett, J. A. (1999). Population Pharmacokinetics of Lamivudine in Adult Human Immunodeficiency Virus-Infected Patients Enrolled in Two Phase III Clinical Trials. Antimicrob. Agents Chemother. 43: 3025-3029 [Abstract] [Full Text]  
• Kashuba, A. D. M., Dyer, J. R., Kramer, L. M., Raasch, R. H., Eron, J. J., Cohen, M. S. (1999). Antiretroviral-Drug Concentrations in Semen: Implications for Sexual Transmission of Human Immunodeficiency Virus Type 1. Antimicrob. Agents Chemother. 43: 1817-1826 [Full Text]  
• Grovit-Ferbas, K., Ferbas, J., Gudeman, V., Sadeghi, S., Goetz, M. B., Giorgi, J. V., Chen, I. S. Y., O'Brien, W. A. (1998). Potential Contributions of Viral Envelope and Host Genetic Factors in a Human Immunodeficiency Virus Type 1-Infected Long-Term Survivor. J. Virol. 72: 8650-8658 [Abstract] [Full Text]  
• Havlir, D. V., Marschner, I. C., Hirsch, M. S., Collier, A. C., Tebas, P., Bassett, R. L., Ioannidis, J. P.A., Holohan, M.K., Leavitt, R., Boone, G., Richman, D. D., The AIDS Clinical Trials Group Study 343 Team, (1998). Maintenance Antiretroviral Therapies in HIV-Infected Subjects with Undetectable Plasma HIV RNA after Triple-Drug Therapy. NEJM 339: 1261-1268 [Abstract] [Full Text]  
• Sun, R., Ku, J., Jayakar, H., Kuo, J.-C., Brambilla, D., Herman, S., Rosenstraus, M., Spadoro, J. (1998). Ultrasensitive Reverse Transcription-PCR Assay for Quantitation of Human Immunodeficiency Virus Type 1 RNA in Plasma. J. Clin. Microbiol. 36: 2964-2969 [Abstract] [Full Text]  
• Lai, C.-L., Chien, R.-N., Leung, N. W.Y., Chang, T.-T., Guan, R., Tai, D.-I., Ng, K.-Y., Wu, P.-C., Dent, J. C., Barber, J., Stephenson, S. L., Gray, D. F., The Asia Hepatitis Lamivudine Study Group, (1998). A One-Year Trial of Lamivudine for Chronic Hepatitis B. NEJM 339: 61-68 [Abstract] [Full Text]  
• Mulato, A. S., Lamy, P. D., Miller, M. D., Li, W.-X., Anton, K. E., Hellmann, N. S., Cherrington, J. M. (1998). Genotypic and Phenotypic Characterization of Human Immunodeficiency Virus Type 1 Variants Isolated from AIDS Patients after Prolonged Adefovir Dipivoxil Therapy. Antimicrob. Agents Chemother. 42: 1620-1628 [Abstract] [Full Text]  
• Dutschman, G. E., Bridges, E. G., Liu, S.-H., Gullen, E., Guo, X., Kukhanova, M., Cheng, Y.-C. (1998). Metabolism of 2',3'-Dideoxy-2',3'-Didehydro-beta -L(-)-5-Fluorocytidine and Its Activity in Combination with Clinically Approved Anti-Human Immunodeficiency Virus beta -D(+) Nucleoside Analogs In Vitro. Antimicrob. Agents Chemother. 42: 1799-1804 [Abstract] [Full Text]  
• Kemp, S. D., Shi, C., Bloor, S., Harrigan, P. R., Mellors, J. W., Larder, B. A. (1998). A Novel Polymorphism at Codon 333 of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Can Facilitate Dual Resistance to Zidovudine and L-2',3'-Dideoxy-3'-Thiacytidine. J. Virol. 72: 5093-5098 [Abstract] [Full Text]  
• Samet, J. H., Freedberg, K. A., Stein, M. D., Lewis, R., Savetsky, J., Sullivan, L., Levenson, S. M., Hingson, R. (1998). Trillion Virion Delay: Time From Testing Positive for HIV to Presentation for Primary Care. Arch Intern Med 158: 734-740 [Abstract] [Full Text]  
• Bartlett, J. A. (1998). Strategies of Antiretroviral Therapy in Adults. The Oncologist 3: 111-118 [Abstract] [Full Text]  
• Hogg, R. S., Heath, K. V., Yip, B., Craib, K. J. P., O'Shaughnessy, M. V., Schechter, M. T., Montaner, J. S. G. (1998). Improved Survival Among HIV-Infected Individuals Following Initiation of Antiretroviral Therapy. JAMA 279: 450-454 [Abstract] [Full Text]  
• Freedberg, K. A., Scharfstein, J. A., Seage III, G. R., Losina, E., Weinstein, M. C., Craven, D. E., Paltiel, A. D. (1998). The Cost-effectiveness of Preventing AIDS-Related Opportunistic Infections. JAMA 279: 130-136 [Abstract] [Full Text]  
• Lee, W. M. (1997). Hepatitis B Virus Infection. NEJM 337: 1733-1745 [Full Text]  
• Hammer, S. M., Squires, K. E., Hughes, M. D., Grimes, J. M., Demeter, L. M., Currier, J. S., Eron, J. J., Feinberg, J. E., Balfour, H. H., Deyton, L. R., Chodakewitz, J. A., Fischl, M. A., Phair, J. P., Pedneault, L., Nguyen, B.-Y., Cook, J. C., The AIDS Clinical Trials Group 320 Study Team, (1997). A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or Less. NEJM 337: 725-733 [Abstract] [Full Text]  
• Gulick, R. M., Mellors, J. W., Havlir, D., Eron, J. J., Gonzalez, C., McMahon, D., Richman, D. D., Valentine, F. T., Jonas, L., Meibohm, A., Emini, E. A., Chodakewitz, J. A., Deutsch, P., Holder, D., Schleif, W. A., Condra, J. H. (1997). Treatment with Indinavir, Zidovudine, and Lamivudine in Adults with Human Immunodeficiency Virus Infection and Prior Antiretroviral Therapy. NEJM 337: 734-739 [Abstract] [Full Text]  
• Bonhoeffer, S., May, R. M., Shaw, G. M., Nowak, M. A. (1997). Virus dynamics and drug therapy. Proc. Natl. Acad. Sci. USA 94: 6971-6976 [Abstract] [Full Text]  
• McDonald, C. K., Kuritzkes, D. R. (1997). Human Immunodeficiency Virus Type 1 Protease Inhibitors. Arch Intern Med 157: 951-959 [Abstract]  
• (1997). Major advances in the treatment of HIV-1 infection. DTB 35: 25-29 [Abstract] [Full Text]  
• Cui, L., Locatelli, L., Xie, M.-Y., Sommadossi, J.-P. (1997). Effect of Nucleoside Analogs on Neurite Regeneration and Mitochondrial DNA Synthesis in PC-12 Cells. J. Pharmacol. Exp. Ther. 280: 1228-1234 [Abstract] [Full Text]  
• Cohn, J. A. (1997). Recent advances: hiv infection–I. BMJ 314: 487-487 [Full Text]  
• Wood, L. (1996). Perinatal Transmission of HIV-1. JAMA 276: 1300-1301 [Abstract]  
• Hammer, S. M., Katzenstein, D. A., Hughes, M. D., Gundacker, H., Schooley, R. T., Haubrich, R. H., Henry, W. K., Lederman, M. M., Phair, J. P., Niu, M., Hirsch, M. S., Merigan, T. C., The AIDS Clinical Trials Group Study 175 Study Tea, (1996). A Trial Comparing Nucleoside Monotherapy with Combination Therapy in HIV-Infected Adults with CD4 Cell Counts from 200 to 500 per Cubic Millimeter. NEJM 335: 1081-1090 [Abstract] [Full Text]  
• Katzenstein, D. A., Hammer, S. M., Hughes, M. D., Gundacker, H., Jackson, J. B., Fiscus, S., Rasheed, S., Elbeik, T., Reichman, R., Japour, A., Merigan, T. C., Hirsch, M. S., The AIDS Clinical Trials Group Study 175 Virology, (1996). The Relation of Virologic and Immunologic Markers to Clinical Outcomes after Nucleoside Therapy in HIV-Infected Adults with 200 to 500 CD4 Cells per Cubic Millimeter. NEJM 335: 1091-1098 [Abstract] [Full Text]  
• Staszewski, S., Loveday, C., Picazo, J. J., Dellamonica, P., Skinhoj, P., Johnson, M. A., Danner, S. A., Harrigan, P. R., Hill, A. M., Verity, L., McDade, H. (1996). Safety and Efficacy of Lamivudine-Zidovudine Combination Therapy in Zidovudine-Experienced Patients: A Randomized Controlled Comparison With Zidovudine Monotherapy. JAMA 276: 111-117 [Abstract]  
• Katlama, C., Ingrand, D., Loveday, C., Clumeck, N., Mallolas, J., Staszewski, S., Johnson, M., Hill, A. M., Pearce, G., McDade, H. (1996). Safety and Efficacy of Lamivudine-Zidovudine Combination Therapy in Antiretroviral-Naive Patients: A Randomized Controlled Comparison With Zidovudine Monotherapy. JAMA 276: 118-125 [Abstract]  
• Carpenter, C. C. J., Fischl, M. A., Hammer, S. M., Hirsch, M. S., Jacobsen, D. M., Katzenstein, D. A., Montaner, J. S. G., Richman, D. D., Saag, M. S., Schooley, R. T., Thompson, M. A., Vella, S., Yeni, P. G., Volberding, P. A. (1996). Antiretroviral Therapy for HIV Infection in 1996: Recommendations of an International Panel. JAMA 276: 146-154 [Abstract]  
• Deyton, L. (1996). Importance of Surrogate Markers in Evaluation of Antiviral Therapy for HIV Infection. JAMA 276: 159-160 [Abstract]  
• Levy, J. A. (1996). Surrogate Markers in AIDS Research: Is There Truth in Numbers?. JAMA 276: 161-162 [Abstract]  
• Phillips, A. N. (1996). Response: HIV-2 and Natural Protection Against HIV-1 Infection. Science 272: 1961-1962  
• Stoeckle, M. Y., Douglas, R. G. Jr (1996). Infectious Diseases. JAMA 275: 1816-1817 [Abstract]  
• Moore, R. D., Keruly, J. C., Chaisson, R. E. (1996). Duration of the Survival Benefit of Zidovudine Therapy in HIV Infection. Arch Intern Med 156: 1073-1077 [Abstract]  
• (1996). 3TC plus AZT: Good Results. AIDS Clin Care 1996: 3-3 [Full Text]  
• (1995). ...AND HIV. JWatch General 1995: 5-5 [Full Text]  
• Merigan, T. C. (1995). A Quarter-Century of Antiviral Therapy. NEJM 333: 1704-1705 [Full Text]